


## PHASE II

# A Trial of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Adult Patients With Recurrent or Progressive Glioblastoma



### Key Inclusion Criteria

- Age ≥18 years
- KPS score ≥60
- Histologically confirmed diagnosis of supratentorial glioblastoma (GBM, grade 4 astrocytoma)
- Radiographically confirmed first recurrence or progression of GBM following initial treatment consisting of surgery and chemoradiation
- Not receiving any antineoplastic therapy, including radiation, for first relapse or recurrence
- Bevacizumab must be an acceptable treatment option
- HLA type restriction: HLA-A\*02:01, HLA-A\*02:06, or HLA-A\*24:02

See ClinicalTrials.gov for comprehensive eligibility criteria.

\*Ombipepimut-S and adegramotide/nelatimotide are nonproprietary names for DSP-7888.

†WT1, a tumor-specific antigen, is expressed in leukemic cells and in many solid tumor types.

ID=intradermally; IV=intravenously; HLA=human leukocyte antigen; KPS=Karnofsky Performance Status.

### Study Locations

Sites in the US, Japan, Korea, and Taiwan are actively recruiting. Please check [www.clinicaltrials.gov](http://www.clinicaltrials.gov) for updates about this study (NCT03149003) and for a listing of clinical study site locations.

### About DSP-7888 Dosing Emulsion

DSP-7888<sup>†</sup> Dosing Emulsion is an intradermally or subcutaneously administered, investigational, synthetic cancer peptide vaccine hypothesized to stimulate an immune response against cancer cells expressing the WT1 protein,<sup>†</sup> and has not yet been approved by the FDA or any other health authorities.

Boston Biomedical, Inc. is a leading developer of next-generation cancer therapeutics designed to inhibit cancer stemness pathways and modify immune responses.

**PHASE II**



# A Trial of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Adult Patients With Recurrent or Progressive Glioblastoma

Boston Biomedical, Inc. is a leading developer of next-generation cancer therapeutics designed to inhibit cancer stemness pathways and modify immune responses.



[www.bostonbiomedical.com](http://www.bostonbiomedical.com)